Doctors Question Scientific Claims Behind Deepinder Goyal's ₹85,000 Temple Device -

Deepinder Goyal, founder of Zomato, has drawn attention to his latest wearable technology, called Temple. However, the device has also sparked debate among medical professionals over its claims of monitoring blood flow to the brain and the scientific evidence supporting its capabilities.

Priced at ₹85,000 for pre-orders, Temple has attracted interest from technology enthusiasts and health-conscious consumers. At the same time, several doctors have questioned whether the device can accurately measure blood flow inside the brain or provide meaningful medical information.

The discussion gained attention after Indian badminton player PV Sindhu was seen wearing the device during this year's World Badminton Championship.

What Is Deepinder Goyal's Temple Wearable?

Temple is a wearable device developed by Deepinder Goyal. It is designed to be attached to the side of the forehead, near the temple, and is presented as a technology that can monitor blood flow-related changes.

The device has attracted interest because of its proposed use in tracking physiological signals associated with brain health. However, its claims have also raised questions about whether a wearable sensor placed on the outside of the head can provide reliable information about blood circulation inside the brain.

The controversy became more prominent after the company began accepting pre-orders at a reported price of ₹85,000.

Doctors Question Temple's Brain Blood Flow Monitoring Claims

Several medical professionals have raised concerns about the scientific basis of Temple's proposed capabilities.

One of the most vocal critics has been Dr Cyriac Philip, a Kochi-based physician known online as The Liver Doc. He questioned whether the device could measure blood flow to the brain, arguing that the sensor appears to monitor blood flow in an artery supplying the face rather than circulation within the brain.

According to his criticism, measuring blood flow in an external artery does not automatically establish that a device can accurately assess cerebral blood circulation.

Dr Philip also questioned the research material associated with the product. He argued that some of the available papers had not undergone peer review, an important process through which independent experts evaluate scientific research before publication.

He further raised concerns about the authorship of positive research findings, suggesting that some of the papers were written by individuals associated with Goyal's scientific team.

These criticisms have brought attention to the importance of independent scientific validation before a health-related technology is marketed to consumers.

Medical Experts Highlight the Difference Between Facial and Brain Blood Flow

Dr Jason Philip also questioned the medical claims associated with Temple.

He argued that the brain receives blood through the internal carotid and vertebral artery systems. According to his assessment, established methods for examining cerebral blood flow include transcranial Doppler ultrasound, which can measure blood flow in the middle cerebral artery, and phase-contrast MRI.

He suggested that an external wearable sensor might detect certain changes in blood flow outside the skull, but that this would not necessarily demonstrate reliable measurement of blood circulation within the brain.

The distinction is important because monitoring blood flow in arteries near the surface of the head is not the same as directly assessing circulation inside the brain.

The concerns raised by these doctors have therefore centred on whether Temple's technology has sufficient evidence to support the health-related claims associated with it.

Deepinder Goyal Responds to Criticism Over Temple

Deepinder Goyal has pushed back against criticism of the wearable and the doubts expressed by medical professionals.

According to the supplied reports, Goyal said he had invested approximately $20 million of his own money in the project and did not need to resort to fraudulent claims.

He also criticised doctors who questioned the device. However, the debate has continued, with critics seeking independent scientific evidence to support Temple's proposed brain blood flow monitoring capabilities.

Financial investment in a technology project, however, does not by itself establish that its medical claims are scientifically accurate. Independent testing, transparent research and peer-reviewed findings remain important for evaluating health-related devices.

Can Temple Compete With Existing Health Wearables?

Wearable technology has become increasingly popular among consumers who want to monitor everyday health and fitness information.

Smartwatches and fitness bands commonly track measurements such as heart rate, physical activity, sleep patterns and, in some models, blood oxygen levels or estimated blood pressure-related information.

Temple proposes a different type of monitoring by focusing on blood flow-related signals near the head. This makes its scientific claims particularly important because consumers may interpret such measurements as indicators of brain health.

For a device marketed around medical or physiological monitoring, clear information about what it measures, how accurately it works and what its readings actually mean is essential.

Conclusion: Independent Scientific Evidence Will Be Important for Temple's Future

Deepinder Goyal's Temple wearable has generated interest because of its ambition to introduce a new approach to health monitoring. However, its reported ₹85,000 pre-order price and claims related to brain blood flow have also attracted questions from medical professionals.

The concerns raised by doctors highlight the need for independent scientific testing and peer-reviewed research before consumers rely on such technology for health-related insights.

While innovation can create new possibilities in wearable technology, strong scientific evidence is necessary to establish whether a device can deliver the capabilities it promises. Temple's future acceptance will depend not only on its technology but also on how convincingly its developers address the questions surrounding its medical claims.